You are here: Home » Reuters » News
Business Standard

Indivior says 2018 profit to fall short after U.S. market hit


(Reuters) - British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.India's Dr.Reddy's Laboratories and U.S.-based Mylan NV received approval from the Food and Drug Administration (FDA) last month to launch a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue.The company said its earlier guidance of $1.13 billion to $1.17 billion in 2018 net revenue and $280 million to $320 million ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Wed, July 11 2018. 12:27 IST